{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T13:53:17Z","timestamp":1789912397778,"version":"4.0.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.ygyno.2022.10.004","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T06:44:53Z","timestamp":1665729893000},"page":"444-451","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Not all stage I and II endometrial cancers are created equal: Recurrence-free survival and cause-specific survival after observation or vaginal brachytherapy alone in all subgroups of early-stage high-intermediate and high-risk endometrial cancer"],"prefix":"10.1016","volume":"167","author":[{"given":"Simone","family":"Garzon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapna","family":"Kollikonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela E.","family":"McGree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivy A.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. John","family":"Weroha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gretchen E.","family":"Glaser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie L.","family":"Langstraat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudha R.","family":"Amarnath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam M.","family":"AlHilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2022.10.004_bb0005","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2022.10.004_bb0010","series-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) - Uterine Neoplasms Version 1","first-page":"2022","author":"NCCN","year":"2022"},{"key":"10.1016\/j.ygyno.2022.10.004_bb0015","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/IGC.0000000000000609","article-title":"ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up","volume":"26","author":"Colombo","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2022.10.004_bb0020","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2022.10.004_bb0025","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0090-8258(91)90086-K","article-title":"Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a gynecologic oncology group study","volume":"40","author":"Morrow","year":"1991","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.10.004_bb0030","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1006\/gyno.1998.4951","article-title":"An analysis of approaches to the management of endometrial cancer in North America: a CTF study","volume":"68","author":"Maggino","year":"1998","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.10.004_bb0035","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/S0140-6736(00)02139-5","article-title":"Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma","volume":"355","author":"Creutzberg","year":"2000","journal-title":"Lancet."},{"key":"10.1016\/j.ygyno.2022.10.004_bb0040","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.ygyno.2003.11.048","article-title":"A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study","volume":"92","author":"Keys","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.10.004_bb0045","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1136\/ijgc-2019-000776","article-title":"High intermediate risk endometrial cancer. What is it?","volume":"29","author":"Eifel","year":"2019","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2022.10.004_bb0050","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0140-6736(09)62163-2","article-title":"Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial","volume":"375","author":"Nout","year":"2010","journal-title":"Lancet."},{"key":"10.1016\/j.ygyno.2022.10.004_bb0055","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.2004.08.159","article-title":"Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the postoperative radiation therapy in endometrial carcinoma trial","volume":"22","author":"Creutzberg","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2022.10.004_bb0060","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1200\/JCO.18.01575","article-title":"Phase III trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel\/carboplatin in high-intermediate and high-risk early stage endometrial Cancer","volume":"37","author":"Randall","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2022.10.004_bb0065","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S1470-2045(19)30395-X","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial","volume":"20","author":"de Boer","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2022.10.004_bb0070","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(19)30416-4","article-title":"Management of high-risk endometrial cancer: are we there yet?","volume":"20","author":"Randall","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2022.10.004_bb0075","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/ijgc-2019-000264","article-title":"A proposal for a new classification of \u201cunfavorable risk criteria\u201d in patients with stage I endometrial cancer","volume":"29","author":"Li","year":"2019","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2022.10.004_bb0080","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/bjc.2015.35","article-title":"Just how accurate are the major risk stratification systems for early-stage endometrial cancer?","volume":"112","author":"Bendifallah","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2022.10.004_bb0085","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijgo.2009.02.012","article-title":"Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium","volume":"105","author":"Pecorelli","year":"2009","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/j.ygyno.2022.10.004_bb0090","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/sj.bjc.6603279","article-title":"Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial","volume":"95","author":"Maggi","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2022.10.004_bb0095","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ygyno.2007.09.029","article-title":"Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study","volume":"108","author":"Susumu","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.10.004_bb0100","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1016\/j.ejca.2010.06.002","article-title":"Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies","volume":"46","author":"Hogberg","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2022.10.004_bb0105","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ygyno.2008.03.020","article-title":"Surgically staged high-risk endometrial cancer: randomized study of adjuvant radiotherapy alone vs. sequential chemo-radiotherapy","volume":"110","author":"Kuoppala","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.10.004_bb0110","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa1813181","article-title":"Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer","volume":"380","author":"Matei","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2022.10.004_bb0115","first-page":"CD003175","article-title":"Adjuvant chemotherapy for endometrial cancer after hysterectomy","author":"Johnson","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ygyno.2022.10.004_bb0120","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S1470-2045(18)30079-2","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial","volume":"19","author":"de Boer","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2022.10.004_bb0125","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(19)30416-4","article-title":"Management of high-risk endometrial cancer: are we there yet?","volume":"20","author":"Randall","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2022.10.004_bb0130","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/bjc.2016.323","article-title":"Patients\u2019 and clinicians\u2019 preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial","volume":"115","author":"ANZGOG","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2022.10.004_bb0135","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy","volume":"38","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2022.10.004_bb0140","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer."},{"key":"10.1016\/j.ygyno.2022.10.004_bb0145","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822018601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822018601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:02:26Z","timestamp":1758772946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825822018601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0090825822018601"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.10.004","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Not all stage I and II endometrial cancers are created equal: Recurrence-free survival and cause-specific survival after observation or vaginal brachytherapy alone in all subgroups of early-stage high-intermediate and high-risk endometrial cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}